GB2264949A - Measles virus recombinant poxvirus vaccine - Google Patents

Measles virus recombinant poxvirus vaccine

Info

Publication number
GB2264949A
GB2264949A GB9309414A GB9309414A GB2264949A GB 2264949 A GB2264949 A GB 2264949A GB 9309414 A GB9309414 A GB 9309414A GB 9309414 A GB9309414 A GB 9309414A GB 2264949 A GB2264949 A GB 2264949A
Authority
GB
United Kingdom
Prior art keywords
recombinant poxvirus
measles virus
foreign dna
vaccine
host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9309414A
Other versions
GB9309414D0 (en
GB2264949B (en
Inventor
Enzo Paoletti
Jill Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virogenetics Corp
Original Assignee
Virogenetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogenetics Corp filed Critical Virogenetics Corp
Priority to GB9500214A priority Critical patent/GB2283021B/en
Publication of GB9309414D0 publication Critical patent/GB9309414D0/en
Publication of GB2264949A publication Critical patent/GB2264949A/en
Application granted granted Critical
Publication of GB2264949B publication Critical patent/GB2264949B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

What is described is a recombinant poxvirus, such as vaccinia virus or canarypox virus, containing foreign DNA from Morbillivirus. In one embodiment, the foreign DNA is expressed in a host by the production of a measles virus glycoprotein. In another embodiment, the foreign DNA is expressed in a host by the production of at least two measles virus glycoproteins. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. By the present invention, cross-protection of dogs against canine distemper is obtained by inoculating the dog with the recombinant poxvirus.
GB9309414A 1990-11-20 1991-11-20 Measles virus recombinant poxvirus vaccine Expired - Lifetime GB2264949B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9500214A GB2283021B (en) 1990-11-20 1991-11-20 A recombinant poxviral vaccine for canine distemper

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62161490A 1990-11-20 1990-11-20
US77686791A 1991-10-22 1991-10-22
PCT/US1991/008703 WO1992008789A1 (en) 1990-11-20 1991-11-20 Measles virus recombinant poxvirus vaccine

Publications (3)

Publication Number Publication Date
GB9309414D0 GB9309414D0 (en) 1993-07-14
GB2264949A true GB2264949A (en) 1993-09-15
GB2264949B GB2264949B (en) 1995-07-05

Family

ID=27089007

Family Applications (2)

Application Number Title Priority Date Filing Date
GB9500214A Expired - Lifetime GB2283021B (en) 1990-11-20 1991-11-20 A recombinant poxviral vaccine for canine distemper
GB9309414A Expired - Lifetime GB2264949B (en) 1990-11-20 1991-11-20 Measles virus recombinant poxvirus vaccine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB9500214A Expired - Lifetime GB2283021B (en) 1990-11-20 1991-11-20 A recombinant poxviral vaccine for canine distemper

Country Status (12)

Country Link
JP (2) JP3617668B2 (en)
AU (1) AU1253892A (en)
BE (1) BE1005908A5 (en)
CA (1) CA2096633A1 (en)
CH (1) CH683921A5 (en)
DE (2) DE4192786B4 (en)
FR (1) FR2669346B1 (en)
GB (2) GB2283021B (en)
IE (2) IE68404B1 (en)
IT (1) IT1252687B (en)
NL (2) NL195058C (en)
WO (1) WO1992008789A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211165B1 (en) 1997-05-09 2001-04-03 The Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5989561A (en) * 1991-03-07 1999-11-23 Virogenetics Corporation Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
KR100242671B1 (en) * 1991-03-07 2000-03-02 고돈 에릭 Genetically engineered vaccine strain
JPH06505397A (en) * 1991-03-20 1994-06-23 ヴァイロジェネティクス　コーポレイション malaria recombinant poxvirus
EP1156102A1 (en) * 1991-06-14 2001-11-21 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
CN1089370C (en) * 1994-12-08 2002-08-21 中国预防医学科学研究院病毒学研究所 Recombination vaccinia virus for expression of measles virus L4 strain hemagglutinin and fusion protein gene
WO1997028265A1 (en) * 1996-02-05 1997-08-07 University Of Massachusetts Medical Center Measles immunization by dna transcription unit inoculation
EP1095948A1 (en) * 1999-10-28 2001-05-02 Universitätsklinikum Freiburg Idiotype vaccines
DE60234018D1 (en) 2001-03-08 2009-11-26 Univ Emory MVA-EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES
AR052743A1 (en) * 2006-04-11 2007-03-28 Inst Nac De Tecnologia Agropec PLASMIDIC TRANSFER VECTOR AND RECOMBINANT CANARYPOX VIRUS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2617715B1 (en) * 1987-07-07 1990-08-31 Transgene Sa VIRAL VECTOR AND RECOMBINANT DNA ENCODING FOR ONE OR MORE SURFACE PROTEINS (HA AND / OR F) OF A MORBILLIVIRUS, INFECTED CELL CULTURE, PROTEINS OBTAINED, VACCINE AND ANTIBODIES OBTAINED
DE10399032I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
FR2632863B2 (en) * 1987-10-29 1990-08-31 Transgene Sa RECOMBINANT FOWLPOX VIRUS AND VACCINES DERIVED FROM SUCH VIRUSES
JPH01218590A (en) * 1988-02-29 1989-08-31 Toa Nenryo Kogyo Kk Rinderpest virus vaccine using recombinant vaccinia virus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
J.gen.Virol. 1988,69,2071-2083 *
J.Virol. 1986,58(2),536-541 *
J.Virol. 1990,64(2),527-533 *
Proc.Natl.Acad.Sci.USA 1988,85,1252-1256 *
Technol.Adv.Vaccine Develop. 1988,321-334 *
Virus Res. 1987,8,373-386 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211165B1 (en) 1997-05-09 2001-04-03 The Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists

Also Published As

Publication number Publication date
GB2283021B (en) 1995-07-05
ITMI913092A0 (en) 1991-11-20
GB2283021A (en) 1995-04-26
FR2669346B1 (en) 1995-07-21
CA2096633A1 (en) 1992-05-21
CH683921A5 (en) 1994-06-15
WO1992008789A1 (en) 1992-05-29
JP2005040129A (en) 2005-02-17
GB9309414D0 (en) 1993-07-14
AU1253892A (en) 1992-06-11
BE1005908A5 (en) 1994-03-08
GB2264949B (en) 1995-07-05
IT1252687B (en) 1995-06-23
NL195095C (en) 2004-01-21
FR2669346A1 (en) 1992-05-22
GB9500214D0 (en) 1995-03-01
NL195058C (en) 2003-07-01
JPH06502996A (en) 1994-04-07
DE4192786B4 (en) 2006-08-24
IE913960A1 (en) 1992-05-20
DE4192786T1 (en) 1994-01-13
IE68404B1 (en) 1996-06-12
NL9900036A (en) 2003-10-01
JP3824619B2 (en) 2006-09-20
JP3617668B2 (en) 2005-02-09
NL9120026A (en) 1993-09-01
ITMI913092A1 (en) 1993-05-20
IE71643B1 (en) 1997-02-26

Similar Documents

Publication Publication Date Title
GB2264949A (en) Measles virus recombinant poxvirus vaccine
GB2269820A (en) Flavivirus recombinant poxvirus vaccine
DE3677494D1 (en) VIRUS VACCINE.
PT91381A (en) PROCESS FOR THE MICROBIOLOGICAL PREPARATION OF HUMAN SERUM ALBUMIN AND OTHER HETEROLOGICAL PROTEINS FROM YEAST
KR900700508A (en) Chimeric glycoprotein containing glycoprotein immune fragments against human respiratory syncytial virus
ATE105334T1 (en) CHIMAERIC GLYCOPROTEINS CONTAINING IMMUNOGENIC SECTIONS OF HUMAN PARAINFLUENZAVIRUS TYPE 3.
WO1999042588A3 (en) Group b streptococcus antigens
ATE119939T1 (en) LINKS.
DE3882599D1 (en) DOG CORONAVIRUS VACCINE.
SG55095A1 (en) Viruses and their use as a vaccine against feline infectious peritonitis virus disease
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
DK0623172T3 (en) Recombinant Marek's disease virus poxvirus vaccine
ES2196018T3 (en) RECOMBINANT ADENOVIRUS VACCINES.
ATE291230T1 (en) USE OF METHODS FOR IDENTIFYING HYDROPHILIC SIGNAL OLIGOPEPTIDES
DE69615772D1 (en) Mild Newcastle disease vaccine
UY26588A1 (en) GM-NEGATIVE EHV MUTANTS
EP0496787A4 (en) Novel infectious bursal disease virus
ATE318300T1 (en) ISOLATED STRAINS OF STAPHYLOCOCCUS AUREUS AND VACCINES PRODUCED THEREFROM
ES482549A0 (en) A METHOD FOR THE PREPARATION OF A HERPES VIRUS COMPOSITION
ATE235553T1 (en) PROTEIN P100FROM HUMAN HERPES VIRUS TYPE 6, THE CORRESPONDING DNA SEQUENCES, THEIR PRODUCTION AND USE
CA2259047A1 (en) Innoculation kits for avoiding maternal immunity

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Expiry date: 20111119